A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Nihar Desai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, …. Hauptthemen laut MEDLINE: Graft vs Host Disease, Antilymphocyte Serum, Hematopoietic Stem Cell Transplantation, Cyclophosphamide. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Anti‐thymocyte globulin (ATG) and post‐transplant cyclophosphamide (PTCy) are both effective drugs for graft‐versus‐host disease (GvHD) prophylaxis, but their combined use remains underexplored. We conducted a retrospective analysis of 582 patients with haematological malignancies who underwent unrelated donor transplantation with Status GvHD prophylaxis consisting of low‐dose ATG (2 mg/kg) and PTCy over a 10‐year period. The median time to neutrophil and platelet engraftment was 18 days (95% CI, 17–19) and 20 days (95% CI, 19–21) respectively. The cumulative incidence of grade III–IV acute Status GvHD at D+100 was 7% (95% CI: 5–9), and the 24‐month incidence of moderate‐to‐severe chronic GvHD was 15.7% (95% CI: 13–19). Clinically significant cytomegalovirus (CMV) and Epstein–Barr virus (EBV) reactivation by D+180 occurred in 20.4% (95% CI: 17–24) and 22.7% (95% CI: 19–26) respectively. At 24 months, the cumulative incidence of NRM was 16.2% (95% CI: 13–19), and relapse was 21.3% (95% CI: 18–25). Graft‐versus‐host disease‐free, relapse‐free survival (GRFS) at 24 months was 49% (95% CI: 44–53), and overall survival (OS) was 68.3% (95% CI: 64–72). Our decade‐long experience supports the safety and efficacy of combining low‐dose ATG with PTCy for GvHD prophylaxis in unrelated donor transplantation. These findings warrant further validation in prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Nihar Desai, Arjun Datt Law, Fotios V Michelis, Dennis Dong Hwan Kim
Zitieren
APA
Desai, N., Rodriguez-Rodriguez, S., Al-Shaibani, E., Alfaro Moya, T., Law, A. D., Novitzky-Basso, I., Pasic, I., Michelis, F. V., Kumar, R., Kim, D. D. H., Mattsson, J., & Viswabandya, A. (2025). A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.70124
Vancouver
Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, et al. A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation. British Journal of Haematology. 2025. doi:10.1111/bjh.70124
BibTeX
@article{Desai2025,
author = {Desai, Nihar and Rodriguez-Rodriguez, Sergio and Al-Shaibani, Eshrak and Alfaro Moya, Tommy and Law, Arjun Datt and Novitzky-Basso, Igor and Pasic, Ivan and Michelis, Fotios V and Kumar, Rajat and Kim, Dennis Dong Hwan and Mattsson, Jonas and Viswabandya, Auro},
title = {A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70124}
}
EUVIMED